Literature DB >> 21281817

Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma.

Frederik C Roos1, Andrew J Evans, Walburgis Brenner, Bill Wondergem, Jeffery Klomp, Pardeep Heir, Olga Roche, Christian Thomas, Heiko Schimmel, Kyle A Furge, Bin T Teh, Joachim W Thüroff, Christian Hampel, Michael Ohh.   

Abstract

Molecular pathways associated with pathogenesis of sporadic papillary renal cell carcinoma (PRCC), the second most common form of kidney cancer, are poorly understood. We analyzed primary tumor specimens from 35 PRCC patients treated by nephrectomy via gene expression analysis and tissue microarrays constructed from an additional 57 paraffin-embedded PRCC samples via immunohistochemistry. Gene products were validated and further studied by Western blot analyses using primary PRCC tumor samples and established renal cell carcinoma cell lines, and potential associations with pathologic variables and survival in 27 patients with follow-up information were determined. We show that the expression of E2-EPF ubiquitin carrier protein, which targets the principal negative regulator of hypoxia-inducible factor (HIF), von Hippel-Lindau protein, for proteasome-dependent degradation, is markedly elevated in the majority of PRCC tumors exhibiting increased HIF1α expression, and is associated with poor prognosis. In addition, we identified multiple hypoxia-responsive elements within the E2-EPF promoter, and for the first time we demonstrated that E2-EPF is a hypoxia-inducible gene directly regulated via HIF1. These findings reveal deregulation of the oxygen-sensing pathway impinging on the positive feedback mechanism of HIF1-mediated regulation of E2-EPF in PRCC.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21281817      PMCID: PMC3070594          DOI: 10.1016/j.ajpath.2010.10.033

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma.

Authors:  Tamotsu Kuroki; Francesco Trapasso; Sai Yendamuri; Ayumi Matsuyama; Hansjuerg Alder; Masaki Mori; Carlo M Croce
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

2.  Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.

Authors:  M Ohh; C W Park; M Ivan; M A Hoffman; T Y Kim; L E Huang; N Pavletich; V Chau; W G Kaelin
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

3.  Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology.

Authors:  Robert J Motzer; Jennifer Bacik; Tania Mariani; Paul Russo; Madhu Mazumdar; Victor Reuter
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

4.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

Review 5.  VHL and HIF signalling in renal cell carcinogenesis.

Authors:  Marcella M Baldewijns; Iris J H van Vlodrop; Peter B Vermeulen; Patricia M M B Soetekouw; Manon van Engeland; Adriaan P de Bruïne
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

Review 6.  Molecular basis of the VHL hereditary cancer syndrome.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

Review 7.  The clinical implications of the genetics of renal cell carcinoma.

Authors:  Inger Rosner; Gennady Bratslavsky; Peter A Pinto; W Marston Linehan
Journal:  Urol Oncol       Date:  2009 Mar-Apr       Impact factor: 3.498

8.  Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.

Authors:  Tobias Klatte; Allan J Pantuck; Jonathan W Said; David B Seligson; Nagesh P Rao; Jeffrey C LaRochelle; Brian Shuch; Amnon Zisman; Fairooz F Kabbinavar; Arie S Belldegrun
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma.

Authors:  Melinda E Sanders; Rosemarie Mick; John E Tomaszewski; Frederic G Barr
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

View more
  14 in total

1.  UBE2S, a novel substrate of Akt1, associates with Ku70 and regulates DNA repair and glioblastoma multiforme resistance to chemotherapy.

Authors:  L Hu; X Li; Q Liu; J Xu; H Ge; Z Wang; H Wang; Z Wang; C Shi; X Xu; J Huang; Z Lin; R O Pieper; C Weng
Journal:  Oncogene       Date:  2016-09-05       Impact factor: 9.867

Review 2.  The ubiquitin system: an essential component to unlocking the secrets of malaria parasite biology.

Authors:  Michael J Hamilton; Michael Lee; Karine G Le Roch
Journal:  Mol Biosyst       Date:  2014-01-30

3.  Large prospective investigation of meat intake, related mutagens, and risk of renal cell carcinoma.

Authors:  Carrie R Daniel; Amanda J Cross; Barry I Graubard; Yikyung Park; Mary H Ward; Nathaniel Rothman; Albert R Hollenbeck; Wong-Ho Chow; Rashmi Sinha
Journal:  Am J Clin Nutr       Date:  2011-12-14       Impact factor: 7.045

4.  UBE2S is associated with malignant characteristics of breast cancer cells.

Authors:  Akter Khondker Ayesha; Toshinori Hyodo; Eri Asano; Naoki Sato; Mohammed A Mansour; Satoko Ito; Michinari Hamaguchi; Takeshi Senga
Journal:  Tumour Biol       Date:  2015-08-06

5.  UBE2S activates NF-κB signaling by binding with IκBα and promotes metastasis of lung adenocarcinoma cells.

Authors:  Jhih-Yun Ho; Hsin-Ying Lu; Hsing-Hsien Cheng; Yu-Chieh Kuo; Yu-Lin Amy Lee; Chia-Hsiung Cheng
Journal:  Cell Oncol (Dordr)       Date:  2021-09-28       Impact factor: 6.730

6.  Dimerization regulates the human APC/C-associated ubiquitin-conjugating enzyme UBE2S.

Authors:  Anna K L Liess; Alena Kucerova; Kristian Schweimer; Dörte Schlesinger; Olexandr Dybkov; Henning Urlaub; Jörg Mansfeld; Sonja Lorenz
Journal:  Sci Signal       Date:  2020-10-20       Impact factor: 9.517

7.  UBE2QL1 is disrupted by a constitutional translocation associated with renal tumor predisposition and is a novel candidate renal tumor suppressor gene.

Authors:  Naomi C Wake; Christopher J Ricketts; Mark R Morris; Elena Prigmore; Susan M Gribble; Anne-Bine Skytte; Michael Brown; Noel Clarke; Rosamonde E Banks; Shirley Hodgson; Andrew S Turnell; Eamonn R Maher; Emma R Woodward
Journal:  Hum Mutat       Date:  2013-10-07       Impact factor: 4.878

8.  Hepatitis C Virus Downregulates Ubiquitin-Conjugating Enzyme E2S Expression To Prevent Proteasomal Degradation of NS5A, Leading to Host Cells More Sensitive to DNA Damage.

Authors:  Hang T Pham; Tram T T Nguyen; Lap P Nguyen; Sang-Seop Han; Yun-Sook Lim; Soon B Hwang
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

9.  Prognostic Role of the Ubiquitin Proteasome System in Clear Cell Renal Cell Carcinoma: A Bioinformatic Perspective.

Authors:  Hongda Guo; Yan Li; Yaxiao Liu; Lipeng Chen; Zhengdong Gao; Lekai Zhang; Nan Zhou; Hu Guo; Benkang Shi
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

10.  E2-EPF UCP regulates stability and functions of missense mutant pVHL via ubiquitin mediated proteolysis.

Authors:  Kyeong-Su Park; Ju Hee Kim; Hee Won Shin; Kyung-Sook Chung; Dong-Soo Im; Jung Hwa Lim; Cho-Rok Jung
Journal:  BMC Cancer       Date:  2015-10-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.